Vax sales lift Glaxo profit; Gates pledges $10 billion for vaccine R&D, delivery

H1N1

> Sales of the H1N1 vaccine helped lift GlaxoSmithKline's profit to $2.6 billion in the fourth quarter. Report

> The Czech Republic says it is in talks with GlaxoSmithKline to see if it can cancel at least part of its scheduled shipment of H1N1 vaccine. Story

> A total of 112 people have been killed by swine flu in Hungary. Story

Vaccine Research

> Bill Gates has pledged to give $10 billion of his fortune to research, develop and deliver new vaccines that can prevent diarrhea and pneumonia. "We must make this the decade of vaccines," Gates said during the World Economic Forum in Davos, Switzerland. Report

> Investigators from Dartmouth Medical School have reported results of a clinical trial showing that a new vaccine against tuberculosis, Mycobacterium vaccae, is effective in preventing tuberculosis in people with HIV infection. Report

> A new study in the February issue of The Pediatric Infectious Disease Journal asserts that a seasonal influenza vaccine is effective in children as young as 6 weeks old. Story

> NanoBio says it's won a key patent for its vaccine emulsion technology. Story

> An experimental vaccine developed using non-infectious virus-like particles has protected macaques and mice against the chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found. Release

Vaccine Market

> The 7-valent pneumococcal conjugate vaccine has been effective in reducing the number of lethal infections among children and infants even as a fatal complication became more common. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.